Informação sobre produto
JCN037 is a potent, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in clinical development for the treatment of malignant brain tumors. JCN037 has been shown to potently inhibit EGFR tyrosine kinase activity in vitro and in vivo, with an IC50 of 0.2 nM and 1 nM respectively. JCN037 has a high affinity for the EGFR, with a Kd of 2.5 nM and it inhibits EGFR-mediated signaling by binding to the ATP site on the EGFR protein. The selectivity profile of JCN037 was characterized by its ability to inhibit tyrosine kinases other than EGFR with an IC50 >100 μM. This molecule also blocks tumor cell proliferation by inhibiting downstream signaling pathways such as epidermal growth factor (EGF) receptor activation and phosphorylation of ERKs and Akt, which are important molecules involved in cell
Propriedades químicas
Consulta técnica sobre: 3D-FSD15431 JCN037
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
